This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

Gleevec remains effective in advanced GIST, with median overall survival of 75.3 months and significant long-term survival rates. Factors like female sex, gastric tumor location, smaller tumors, and ...

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor. Imatinib, as a receptor-type tyrosine kinase inhibitor (TKI), becomes a first-line drug for adjuvant therapy and prognosis.

Kura Oncology, Inc. announced the initiation of the KOMET-015 Phase 1 clinical trial, which will evaluate the safety and effectiveness of ziftomenib, an investigational menin inhibitor, in combination ...

In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “ammunition in the war against cancer.” Along with a picture of the Gleevec pills, ...

The FDA approved an oral solution of imatinib for multiple different cancer types. The FDA approved an oral solution of imatinib (Imkeldi) for the treatment of multiple cancer types. 1 Imatinib ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first ...

Imkeldi is supplied as a strawberry-flavored oral solution in a 140mL child resistant tamper-evident bottle. The Food and Drug Administration (FDA) has approved ...

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia. The FDA has approved imatinib oral solution (Imkeldi) for the treatment of ...